TL;DR: Aetna, a CVS Health company, modified CPB 1035 covering rozanolixizumab-noli (Rystiggo) for generalized myasthenia gravis, effective December 11, 2025. Billing teams must verify antibody status, MGFA classification, MG-ADL scores, and prior treatment history before submitting claims under HCPCS J9333.
Aetna's rozanolixizumab-noli coverage policy under CPB 1035 Aetna sets tight gatekeeping criteria for this drug — and the exclusion language around combination therapy is the sharpest edge in the policy. If your neurology or infusion practice bills J9333 for Rystiggo, you need to know exactly where Aetna draws the line before claims go out the door.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Rozanolixizumab-noli (Rystiggo) — CPB 1035 |
| Policy Code | CPB 1035 |
| Change Type | Modified |
| Effective Date | December 11, 2025 |
| Impact Level | High |
| Specialties Affected | Neurology, Infusion Therapy, Specialty Pharmacy, Rare Disease |
| Key Action | Confirm AChR/MuSK antibody status, MGFA class II–IV, MG-ADL ≥ 5, and prior therapy history before submitting precertification for J9333 |
Aetna Rozanolixizumab-noli Coverage Criteria and Medical Necessity Requirements 2025
Aetna's coverage policy for Rystiggo is narrow by design. Medical necessity approval requires meeting every criterion in a four-part test — not a subset. Miss one, and you're looking at a claim denial before the drug ever ships.
Here's the full gate your patient must clear for initial approval:
1. Antibody positivity. The member must be anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. This is a lab result, not a clinical impression. Make sure it's documented in the chart and attached to the prior authorization request.
2. MGFA classification. The Myasthenia Gravis Foundation of America clinical classification must be II, III, or IV. Class I (ocular only) does not qualify. Class V (intubation) is also excluded. Know where your patient falls before you submit.
3. MG-ADL score. The MG Activities of Daily Living total score must be 5 or higher. This is a scored instrument — document the actual number, not just "severe disease." Reviewers will check.
4. Prior therapy failure. The member must meet at least one of three paths:
| # | Covered Indication |
|---|---|
| 1 | Inadequate response or intolerable adverse event to at least two immunosuppressive therapies over at least 12 months (azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, or tacrolimus) |
| 2 | Inadequate response or intolerable adverse event to at least one immunosuppressive therapy plus IVIG over at least 12 months |
| 3 | Documented clinical reason to avoid both immunosuppressive agents and IVIG |
That third path matters. If your patient has a contraindication to standard therapy, document it explicitly. Aetna's reviewers are not going to infer it.
Prior authorization is required for all Aetna members on applicable commercial plans. Call (866) 752-7021 or fax the SMN form to (888) 267-3277 to start the process. Don't skip this step — Rystiggo is not a drug you bill and backfill authorization on later.
Reauthorization follows a simpler standard. Aetna considers continuation medically necessary when the member shows no unacceptable toxicity, no disease progression, and a positive response — defined as improvement in MG-ADL score, MG Manual Muscle Test (MMT), or MG Composite. Collect those scores at every visit. They are your reauthorization evidence.
Aetna Rystiggo Exclusions and Non-Covered Indications
The combination therapy exclusion is the one that will catch billing teams off guard. Aetna will not cover rozanolixizumab-noli when used alongside another neonatal Fc receptor (FcRn) blocker or a complement inhibitor.
Specifically excluded combinations:
| # | Excluded Procedure |
|---|---|
| 1 | Rystiggo + Vyvgart (efgartigimod alfa-fcab, J9332) — FcRn blocker on FcRn blocker |
| 2 | Rystiggo + Vyvgart Hytrulo — same class, same exclusion |
| 3 | Rystiggo + Soliris (eculizumab, J1299) — complement inhibitor combination |
| 4 | Rystiggo + Ultomiris (ravulizumab-cwvz, J1303) — complement inhibitor combination |
| 5 | Rystiggo + Zilbrysq (zilucoplan) — complement inhibitor combination |
This is not an unusual move by Aetna. The same stacking logic appeared in their efgartigimod policy (CPB 1002). The pattern is consistent: Aetna will not pay for two biologics targeting overlapping mechanisms in gMG simultaneously.
If your patient is transitioning between agents, timing matters. A member switching from Vyvgart to Rystiggo needs a clean break documented in the record. If both show up on the same claim period, expect a denial.
All other indications for rozanolixizumab-noli are considered experimental, investigational, or unproven by Aetna. Rystiggo billing outside of gMG with the criteria above will not be reimbursed under commercial plans.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| gMG — AChR or MuSK antibody positive, MGFA II–IV, MG-ADL ≥ 5, failed ≥2 immunosuppressives (12+ months) | Covered | J9333, G70.0, G70.1 | Prior authorization required; bill CPT 96369 or 96372 for administration |
| gMG — AChR or MuSK antibody positive, MGFA II–IV, MG-ADL ≥ 5, failed ≥1 immunosuppressive + IVIG (12+ months) | Covered | J9333, G70.0, G70.1 | Prior authorization required; document IVIG trial separately |
| gMG — documented clinical contraindication to immunosuppressives and IVIG | Covered | J9333, G70.0, G70.1 | Clinical rationale must be explicit in chart notes; prior authorization required |
| gMG — continuation/reauthorization with documented positive response | Covered | J9333, G70.0, G70.1 | Requires MG-ADL, MMT, or MG Composite improvement; no unacceptable toxicity |
| Rystiggo combined with Vyvgart, Vyvgart Hytrulo, Soliris, Ultomiris, or Zilbrysq | Not Covered | J9333 + J9332, J1299, J1303 | Combination with FcRn blocker or complement inhibitor is excluded |
| Any indication outside gMG | Not Covered / Experimental | J9333 | All other uses considered experimental, investigational, or unproven |
Aetna Rystiggo Billing Guidelines and Action Items 2025
The effective date is December 11, 2025. If you haven't already, these steps need to happen now.
| # | Action Item |
|---|---|
| 1 | Confirm your charge capture includes J9333 at the correct unit. HCPCS J9333 is billed per 1 mg of rozanolixizumab-noli. Rystiggo is dosed at 7 mg/kg weekly for six weeks. Do the weight-based math per patient and set up your charge capture accordingly. Under-billing units leaves money on the table; over-billing creates audit exposure. |
| 2 | Check your administration code selection. Rystiggo is given subcutaneously. Use CPT 96369 (subcutaneous infusion, initial, up to one hour) as your primary administration code. CPT 96371 applies if you establish a new infusion site. CPT 96372 covers subcutaneous or intramuscular therapeutic injections when the encounter is straightforward. CPT 96401 is listed in the policy but applies to non-hormonal anti-neoplastic chemotherapy administration — confirm with your billing consultant before using it here. |
| 3 | Build a prior authorization checklist specific to CPB 1035. Your checklist should require: (a) AChR or MuSK antibody lab result, (b) MGFA class documented by the treating neurologist, (c) current MG-ADL total score, (d) a prior therapy log showing dates, agents, and reason for discontinuation or failure, and (e) IVIG trial dates if applicable. Missing any of these at submission will delay auth and delay treatment. |
| 4 | Scrub claims for combination therapy conflicts before submission. Pull a report of active specialty drug claims for any patient you're billing J9333 for. Look for concurrent J9332 (Vyvgart), J1299 (Soliris), or J1303 (Ultomiris) on overlapping dates. A claim denial on combination grounds is avoidable — it just takes a pre-bill audit step. |
| 5 | Set up reauthorization tracking tied to MG outcome scores. Continuation approval requires documented improvement. If your neurology team isn't scoring MG-ADL, MMT, and MG Composite at each visit, your reauth will lack the evidence Aetna expects. Build the scoring into your visit workflow now, not after the first reauth request gets denied. |
| 6 | Verify ICD-10 coding against MGFA classification. Use G70.0 (myasthenia gravis without exacerbation) or G70.1 (myasthenia gravis with exacerbation) depending on the patient's current status. Both codes are accepted under this policy. Don't default to one without clinical support for it. |
| 7 | Talk to your compliance officer if you're managing patients transitioning from Vyvgart or another excluded agent. The timing and documentation of those transitions matter under this coverage policy. If there's any overlap in claim dates, you need a defensible record. Don't navigate that alone — loop in compliance before the claim goes out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Rozanolixizumab-noli Under CPB 1035
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9333 | HCPCS | Injection, rozanolixizumab-noli, 1 mg |
Administration CPT Codes (Related to CPB 1035)
| Code | Type | Description |
|---|---|---|
| 96369 | CPT | Subcutaneous infusion for therapy or prophylaxis; initial, up to 1 hour |
| 96371 | CPT | Additional pump set-up with establishment of new subcutaneous infusion site(s) |
| 96372 | CPT | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
| 96401 | CPT | Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic |
Referenced Drug HCPCS Codes (Excluded Combination Agents and Prior Therapy Agents)
These codes appear in the policy as context — either as excluded combination agents or as prior therapy options that must be tried before approval.
| Code | Type | Description | Context |
|---|---|---|---|
| J9332 | HCPCS | Injection, efgartigimod alfa-fcab, 2 mg | Excluded combination agent (Vyvgart) |
| J1299 | HCPCS | Injection, eculizumab, 2 mg | Excluded combination agent (Soliris) |
| J1303 | HCPCS | Injection, ravulizumab-cwvz, 10 mg | Excluded combination agent (Ultomiris) |
| J7500 | HCPCS | Azathioprine, oral, 50 mg | Prior therapy — immunosuppressive |
| J7501 | HCPCS | Azathioprine, parenteral, 100 mg | Prior therapy — immunosuppressive |
| J7507 | HCPCS | Tacrolimus, immediate release, oral, 1 mg | Prior therapy — immunosuppressive |
| J7508 | HCPCS | Tacrolimus, extended release (Astagraf XL), oral, 0.1 mg | Prior therapy — immunosuppressive |
| J7509 | HCPCS | Methylprednisolone oral, per 4 mg | Prior therapy — corticosteroid |
| J7510 | HCPCS | Prednisolone oral, per 5 mg | Prior therapy — corticosteroid |
| J7512 | HCPCS | Prednisone, immediate release or delayed release, oral, 1 mg | Prior therapy — corticosteroid |
| J7515 | HCPCS | Cyclosporine, oral, 25 mg | Prior therapy — immunosuppressive |
| J7516 | HCPCS | Injection, cyclosporine, 250 mg | Prior therapy — immunosuppressive |
| J7518 | HCPCS | Mycophenolic acid, oral, 180 mg | Prior therapy — immunosuppressive |
| J7519 | HCPCS | Injection, mycophenolate mofetil, 10 mg | Prior therapy — immunosuppressive |
| J8540 | HCPCS | Dexamethasone, oral, 0.25 mg | Prior therapy — corticosteroid |
| J9260 | HCPCS | Injection, methotrexate sodium, 50 mg | Prior therapy — immunosuppressive |
| J0702 | HCPCS | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Referenced corticosteroid |
| J1020 | HCPCS | Injection, methylprednisolone acetate, 20 mg | Referenced corticosteroid |
| J1030 | HCPCS | Injection, methylprednisolone acetate, 40 mg | Referenced corticosteroid |
| J1040 | HCPCS | Injection, methylprednisolone acetate, 80 mg | Referenced corticosteroid |
| J1094 | HCPCS | Injection, dexamethasone acetate, 1 mg | Referenced corticosteroid |
| J1100 | HCPCS | Injection, dexamethasone sodium phosphate, 1 mg | Referenced corticosteroid |
| J1720 | HCPCS | Injection, hydrocortisone sodium succinate, up to 100 mg | Referenced corticosteroid |
| J2650 | HCPCS | Injection, prednisolone acetate, up to 1 ml | Referenced corticosteroid |
| J2920 | HCPCS | Injection, methylprednisolone sodium succinate, up to 40 mg | Referenced corticosteroid |
| J2930 | HCPCS | Injection, methylprednisolone sodium succinate, up to 125 mg | Referenced corticosteroid |
Key ICD-10-CM Diagnosis Codes
| Code | Description |
|---|---|
| G70.0 | Myasthenia gravis without exacerbation |
| G70.1 | Myasthenia gravis with exacerbation |
Get the Full Picture for CPT 96369
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.